Xencor | XNCR - Выручка от реализации





Продажи Изменить Дата
AbbVie USD 15B 1.62B 2026-03
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Amgen USD 8.62B 1.28B 2026-03
Arrowhead Research USD 73.74M 190.29M 2026-03
AstraZeneca USD 15.29B 213M 2026-03
Biogen USD 2.25B 30M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Cytokinetics USD 19.35M 1.59M 2026-03
GlaxoSmithKline GBP 7.63B 991M 2026-03
J&J USD 24.1B 500M 2026-03
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.29B 110M 2026-03
Novartis USD 13.11B 226M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Xencor USD 4.51M 23.73M 2026-03